Meridian set to acquire Gull for $25 million
This article was originally published in Clinica
Executive Summary
Meridian Diagnostics has agreed in principle to buy Gull Laboratories, which is 62%-owned by German company Fresenius, for $3 per share in cash, in a deal worth around $25 million. Gull and Fresenius revealed two weeks ago that negotiations were underway with an unnamed company when Gull announced it expected to record a substantial loss in the second quarter (see Clinica No 817, p 9).